Eli Lilly & Co. stock outperforms competitors on strong trading day
Shares of Eli Lilly & Co. LLY rallied 3.26% to $864.90 Monday, on what proved to be an all-around great trading session for ...
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped
First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...
Investor's Business Daily on MSN18h
Novo Nordisk Finds A New Way To Rival Eli Lilly. But Shares Tumble.
Novo Nordisk stock dropped Monday after the drugmaker licensed a Chinese competitor's weight-loss drug for $200 million up ...
BioSpace20h
Novo Challenges Lilly With up to $2B Bet for Triple-G Obesity Drug From Chinese Biotech
Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a ...
5 Reasons It's Not Too Late to Buy Eli Lilly Stock
Eli Lilly (LLY 1.80%) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable ...
Eli Lilly: Growth With Higher Margins
Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...
STAT13d
Eli Lilly’s Dave Ricks takes home $114 million as obesity drugs fuel company’s fortunes
Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.
Eli Lilly & Co (LLY) Receives a Buy from Berenberg Bank
Berenberg Bank analyst Kerry Holford maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on March 21 and set a price target ...
Yahoo Finance1d
Lilly, Novo expand DTC reach of obesity meds after compound win
To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Eli Lilly and Novo Nordisk have scored big wins from the FDA in recent months, as the agency cracks down on ...